

Appendix 3: QOF Technical changes ( <u>underlined text to signify wording change</u> ) Current ID	Current indicator	New ID	New indicator	Change and rationale
CHOL003	Percentage of patients on the QOF Coronary Heart Disease, Peripheral Arterial Disease, Stroke/TIA or Chronic Kidney Disease Register who are currently prescribed a statin, or where a statin is declined or clinically unsuitable, another lipid-lowering therapy	CHOL003	Percentage of patients on the QOF Coronary Heart Disease (CHD), Peripheral Arterial Disease (PAD), Stroke/ Transient Ischaemic Attack (TIA) or Chronic Kidney Disease (CKD) Register who are currently prescribed a statin, or where a statin is declined or clinically unsuitable, another lipid-lowering therapy	<ul style="list-style-type: none"> <li>Removed icosapent ethyl from the other lipid lowering therapies cluster as only NICE recommended for use with, rather than instead of, a statin.</li> </ul>
CHOL004	Percentage of patients on the QOF Coronary Heart Disease (CHD), Peripheral Arterial Disease (PAD), or Stroke/ Transient Ischaemic Attack (TIA) Register, who have a recording of LDL (Low-density Lipoprotein) cholesterol in the preceding 12 months that is 2.0 mmol/L or	CHOL004	Percentage of patients on the QOF Coronary Heart Disease (CHD), Peripheral Arterial Disease (PAD), or Stroke/Transient Ischaemic Attack (TIA) Register, <u>with the most recent cholesterol measurement</u> in the preceding 12 months showing as $\leq 2.0$ mmol/L if it was an LDL	<ul style="list-style-type: none"> <li>Technical change made to amend how the indicators measure cases where measures of both HDL and LDL are taken at different points in time. <a href="#">NICE Indicator IND278: Cardiovascular disease prevention: cholesterol treatment target (secondary prevention)</a>  </li> </ul>

	lower or where LDL cholesterol is not recorded a recording of non-HDL (High-density Lipoprotein) cholesterol in the preceding 12 months that is 2.6 mmol/L or lower.		(Low-density Lipoprotein) cholesterol reading or $\leq 2.6$ mmol/L if it was a non-HDL (High-density Lipoprotein) cholesterol reading. <u>For multiple readings on the latest date the LDL reading takes priority.</u>	<a href="#">Indicators   NICE</a> (published 27 November 2024)
<b>DM022</b>	The percentage of patients with diabetes aged 40 years and over, with no history of cardiovascular disease and without moderate or severe frailty, who are currently treated with a statin (excluding patients with type 2 diabetes and a CVD risk score of <10% recorded in the preceding 3 years)	<b><u>DM034</u></b>	The percentage of patients with diabetes, on the register, aged 40 years or over, with no history of CVD and without moderate or severe frailty, who are currently treated with a statin (excluding patients with type 2 diabetes and a CVD risk score of <10% recorded in the preceding 3 years), or <u>where a statin is declined or clinically unsuitable, another lipid-lowering therapy.</u>	<ul style="list-style-type: none"> <li>Other lipid lowering therapy cluster added to align with updated NICE indicator on which QOF is based. <a href="#">NICE Indicator IND275: Diabetes: -lowering therapies for primary prevention of CVD (40 years and over)   Indicators   NICE</a> (published 27 November 2024)</li> </ul>
<b>DM023</b>	The percentage of patients with diabetes and a history of cardiovascular disease (excluding haemorrhagic stroke) who are	<b><u>DM035</u></b>	The percentage of patients with diabetes, on the register and a history of CVD (excluding haemorrhagic stroke) who are	<ul style="list-style-type: none"> <li>Other lipid lowering therapy cluster added to align with updated NICE indicator on which QOF is based.</li> </ul>

	currently treated with a statin		currently treated with a statin, or <u>where a statin is declined or clinically unsuitable, another lipid-lowering therapy.</u>	<a href="#">NICE Indicator IND276: Diabetes: lipid-lowering therapies for secondary prevention of CVD   Indicators   NICE</a> (published 27 November 2024)
<b>DM033</b>	The percentage of patients with diabetes, on the register, without moderate or severe frailty in whom the last blood pressure reading (measured in the preceding 12 months) is 140/90 mmHg or less (or equivalent home blood pressure reading)):	<b><u>DM036</u></b>	The percentage of patients with diabetes, on the register, <u>aged 79 years and under</u> without moderate or severe frailty in whom the last blood pressure reading (measured in the preceding 12 months) is 140/90 mmHg or less (or equivalent home blood pressure reading)	<ul style="list-style-type: none"> <li>• '79 years and under' age criteria added to align with updated NICE indicator on which QOF is based. <a href="#">NICE Indicator IND249: Diabetes: blood pressure (without moderate or severe frailty)   Indicators   NICE</a> (published 19 August 2023)</li> </ul>
<b>AST011</b>	The percentage of patients with a diagnosis of asthma on or after 1 April 2023 with either: 1 A record of quality assured spirometry and one other objective test (FeNO or, bronchodilator reversibility or peak flow variability) between 3	<b><u>AST012</u></b>	The percentage of patients with a new diagnosis of asthma on or after 1 April 2025 <u>with a record of an objective test between 3 months before or 3 months after diagnosis.</u>	<ul style="list-style-type: none"> <li>• Removal of reliance on spirometry as main objective test to align with <a href="#">NICE Guideline NG25   Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN)   Guidance   NICE</a></li> </ul>

	<p>months before and 6 months after diagnosis; or</p> <p>2 If newly registered in the preceding 12 months with a diagnosis of asthma recorded on or after 1 April 2023 but no record of objective tests being performed at the date of registration, with a quality assured spirometry and one other objective test (FeNO) or, bronchodilator reversibility or peak flow variability) recorded within 6 months of registration</p>			(published 27 November 2024)
<b>AST007</b>	<p>The percentage of patients with asthma on the register, who have had an asthma review in the preceding 12 months that includes an assessment of asthma control using a validated asthma control questionnaire, a recording of the number of exacerbations, an assessment of inhaler</p>	<b>AST007</b>	<p>The percentage of patients with asthma on the register, who have had an asthma review in the preceding 12 months that includes an assessment of asthma control, a recording of the number of exacerbations and a written personalised action plan.</p>	<ul style="list-style-type: none"> <li>Removal of requirement to use a validated asthma control questionnaire and an assessment of inhaler technique to align with <a href="#">NICE Guideline NG25   Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN)   Guidance   NICE</a> (published 27 November 2024)</li> </ul>

	technique and a written personalised action plan			
<b>AF008</b>	Percentage of patients on the QOF Atrial Fibrillation register and with a CHA <sub>2</sub> DS <sub>2</sub> -VASc score of 2 or more who were prescribed a direct-acting oral anticoagulant (DOAC), or, where a DOAC was declined or clinically unsuitable, a Vitamin K antagonist.	<b>AF008</b>	Percentage of patients on the QOF Atrial Fibrillation register and with a CHA <sub>2</sub> DS <sub>2</sub> -VASc score of 2 or more, who were prescribed a direct-acting oral anticoagulant (DOAC), or, where a DOAC was declined or clinically unsuitable, a Vitamin K antagonist.	<ul style="list-style-type: none"> <li>• Invite PCA added in response to feedback, to align with indicators of a similar type</li> </ul>